Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus platinum-based chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma
ChiCTR2500105814Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in head and neck squamous cell carcinoma (HNSCC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Objective Response Rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500105814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105814.